Cargando…
COVID-19 vaccine platforms: Delivering on a promise?
The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century w...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381795/ https://www.ncbi.nlm.nih.gov/pubmed/34033528 http://dx.doi.org/10.1080/21645515.2021.1911204 |
_version_ | 1783741434195607552 |
---|---|
author | Verdecia, Mark Kokai-Kun, John F. Kibbey, Maura Acharya, Sarita Venema, Jaap Atouf, Fouad |
author_facet | Verdecia, Mark Kokai-Kun, John F. Kibbey, Maura Acharya, Sarita Venema, Jaap Atouf, Fouad |
author_sort | Verdecia, Mark |
collection | PubMed |
description | The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century with the development of technologies that expanded the ability to create novel vaccines. Since then, there has been continued technological advancement in vaccine development. The resulting platforms provide the promise for solutions for many infectious diseases, including those that have been with us for decades as well as those just now emerging. Each vaccine platform represents a different technology with a unique set of advantages and challenges, especially when considering manufacturing. Therefore, it is essential to understand each platform as a separate product and process with its specific quality considerations. This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each. |
format | Online Article Text |
id | pubmed-8381795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-83817952021-08-24 COVID-19 vaccine platforms: Delivering on a promise? Verdecia, Mark Kokai-Kun, John F. Kibbey, Maura Acharya, Sarita Venema, Jaap Atouf, Fouad Hum Vaccin Immunother Review The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century with the development of technologies that expanded the ability to create novel vaccines. Since then, there has been continued technological advancement in vaccine development. The resulting platforms provide the promise for solutions for many infectious diseases, including those that have been with us for decades as well as those just now emerging. Each vaccine platform represents a different technology with a unique set of advantages and challenges, especially when considering manufacturing. Therefore, it is essential to understand each platform as a separate product and process with its specific quality considerations. This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each. Taylor & Francis 2021-05-25 /pmc/articles/PMC8381795/ /pubmed/34033528 http://dx.doi.org/10.1080/21645515.2021.1911204 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Review Verdecia, Mark Kokai-Kun, John F. Kibbey, Maura Acharya, Sarita Venema, Jaap Atouf, Fouad COVID-19 vaccine platforms: Delivering on a promise? |
title | COVID-19 vaccine platforms: Delivering on a promise? |
title_full | COVID-19 vaccine platforms: Delivering on a promise? |
title_fullStr | COVID-19 vaccine platforms: Delivering on a promise? |
title_full_unstemmed | COVID-19 vaccine platforms: Delivering on a promise? |
title_short | COVID-19 vaccine platforms: Delivering on a promise? |
title_sort | covid-19 vaccine platforms: delivering on a promise? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381795/ https://www.ncbi.nlm.nih.gov/pubmed/34033528 http://dx.doi.org/10.1080/21645515.2021.1911204 |
work_keys_str_mv | AT verdeciamark covid19vaccineplatformsdeliveringonapromise AT kokaikunjohnf covid19vaccineplatformsdeliveringonapromise AT kibbeymaura covid19vaccineplatformsdeliveringonapromise AT acharyasarita covid19vaccineplatformsdeliveringonapromise AT venemajaap covid19vaccineplatformsdeliveringonapromise AT atouffouad covid19vaccineplatformsdeliveringonapromise |